Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ex vivo interleukin-12-priming during CD8
+
t cell activation dramatically improves adoptive t cell transfer antitumor efficacy in a lymphodepleted host
Journal of the American College of Surgeons, Volume 214, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Background: Clinical application of adoptive T cell therapy has been hindered by an inability to generate adequate numbers of nontolerized, functionally active, tumor-specific T cells, which can persist in vivo. In order to address this, we evaluated the impact of interleukin (IL)-12 signaling during tumor-specific CD8 + T cell priming in terms of persistence and antitumor efficacy using an established B16 melanoma tumor adoptive therapy model. Study Design: B6 mice were injected subcutaneously with B16 melanoma tumor cells. On day 12 of tumor growth, mice were preconditioned with cyclophosphamide (4mg dose, intraperitoneally), and 1 day later were treated by adoptive transfer of tumor-specific pmel-1 CD8 + T cells primed ex vivo 3 days earlier with both IL-12 and antigen (hGP100 25-33 peptide) or antigen only. Tumors were measured biweekly, and infused donor T cells were analyzed for persistence, localization to the tumor, phenotype, and effector function. Results: Adoptive transfer of tumor-specific CD8 + T cells primed with IL-12 was significantly more effective in reducing tumor burden in mice preconditioned with cyclophosphamide compared with transfer of T cells primed without IL-12. This enhanced antitumor response was associated with increased frequencies of infused T cells in the periphery and tumor as well as elevated expression of effector molecules including granzyme B and interferon-γ (IFNγ). Conclusions: Our findings demonstrate that ex vivo priming of tumor-specific CD8 + T cells with IL-12 dramatically improves their in vivo persistence and therapeutic ability on transfer to tumor-bearing mice. These findings can be directly applied as novel clinical trial strategies. © 2012 by the American College of Surgeons.
Authors & Co-Authors
Rubinstein, Mark P.
United States, Charleston
Medical University of South Carolina
Cloud, Colleen A.
United States, Charleston
Medical University of South Carolina
Garrett, Tracy E.
United States, Charleston
Medical University of South Carolina
Moore, Caitlin J.
United States, Charleston
Medical University of South Carolina
Schwartz, Kristina M.
United States, Charleston
Medical University of South Carolina
Johnson, C. Bryce
United States, Charleston
Medical University of South Carolina
Craig, David H.
United States, Charleston
Medical University of South Carolina
Salem, Mohamed Labib
Egypt, Tanta
Faculty of Science
Paulos, Chrystal Mary
United States, Charleston
Medical University of South Carolina
Cole, David J.
United States, Charleston
Medical University of South Carolina
Statistics
Citations: 34
Authors: 10
Affiliations: 2
Identifiers
Doi:
10.1016/j.jamcollsurg.2011.12.034
ISSN:
10727515
Research Areas
Cancer